Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study

Axsome Therapeutics, Inc. (AXSM) announced that it has initiated the phase III ENGAGE study evaluating its investigational therapy, solriamfetol, for treating adult patients with binge eating disorder (BED).Solriamfetol is presently marketed in the United States under the brand name Sunosi for the treatment of narcolepsy.The double-blind, placebo-controlled phase III study will evaluate the safety and efficacy of solriamfetol (150 mg or 300 mg) in adult patients with BED. The primary endpoint of the study i ...